Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial (Q27851705)

10 January 2018

title

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial (English)

1 reference

10 January 2018

multicenter clinical trial

main subject

phase III clinical trial

0 references

0 references

1 reference

1 reference

3

Holger Eidtmann

0 references

Michael Untch

25

Michael Untch

0 references

Evandro de Azambuja

5

Evandro de Azambuja

0 references

Martine Piccart-Gebhart

27

Martine Piccart-Gebhart

0 references

Zsolt Horváth

Zsolt Horváth

14

0 references

Serena Di Cosimo

Serena Di Cosimo

4

0 references

Henry Leonidas Gómez

Henry Gómez

7

0 references

Vladimir Semiglazov

Vladimir Semiglazov

20

0 references

Aron Goldhirsch

12

Aron Goldhirsch

1 reference

10 January 2018

author name string

José Baselga

1

1 reference

10 January 2018

Ian Bradbury

2

1 reference

10 January 2018

Claudia Aura

6

1 reference

10 January 2018

Phuong Dinh

8

1 reference

10 January 2018

Karine Fauria

9

1 reference

10 January 2018

Veerle Van Dooren

10

1 reference

10 January 2018

Gursel Aktan

11

1 reference

10 January 2018

Tsai-Wang Chang

13

1 reference

10 January 2018

Maria Coccia-Portugal

15

1 reference

10 January 2018

Julien Domont

16

1 reference

10 January 2018

Ling-Min Tseng

17

1 reference

10 January 2018

Georg Kunz

18

1 reference

10 January 2018

Joo Hyuk Sohn

19

1 reference

10 January 2018

Guillermo Lerzo

21

1 reference

10 January 2018

Marketa Palacova

22

1 reference

10 January 2018

Volodymyr Probachai

23

1 reference

10 January 2018

Lajos Pusztai

24

1 reference

10 January 2018

Richard D Gelber

26

1 reference

10 January 2018

NeoALTTO Study Team

28

1 reference

10 January 2018

language of work or name

English

0 references

publication date

17 January 2012

1 reference

10 January 2018

published in

The Lancet

1 reference

10 January 2018

volume

379

1 reference

10 January 2018

issue

9816

1 reference

10 January 2018

page(s)

633-640

1 reference

10 January 2018

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

Trastuzumab--mechanism of action and use in clinical practice

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

ERBB receptors and cancer: the complexity of targeted inhibitors

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705192

Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18

27 November 2018

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961847-3

inferred from DOI database lookup

7 January 2021

based on heuristic

A sharper Bonferroni procedure for multiple tests of significance

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961847-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0140-6736(11)61847-3

1 reference

10 January 2018

OpenCitations bibliographic resource ID

1200329

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

10 January 2018

PubMed ID

22257673

1 reference

10 January 2018